Cardiac substructures exposure in left-sided breast cancer radiotherapy: Is the mean heart dose a reliable predictor of cardiac toxicity?


Journal

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique
ISSN: 1769-6658
Titre abrégé: Cancer Radiother
Pays: France
ID NLM: 9711272

Informations de publication

Date de publication:
May 2021
Historique:
received: 18 06 2020
revised: 11 07 2020
accepted: 03 09 2020
pubmed: 12 1 2021
medline: 14 5 2021
entrez: 11 1 2021
Statut: ppublish

Résumé

This study aimed to assess radiation dose distribution to cardiac subvolumes in left-sided breast cancer radiotherapy (LBCRT) and to clarify whether the mean heart dose (MHD) reliably reflects cardiac substructures exposure. Fifty women referred for adjuvant LBCRT were prospectively evaluated. All patients received 3D-conformal hypofractionated radiotherapy (40Gy delivered in 15 fractions of 2.67Gy±boost of 13.35Gy). Cardiac substructures were contoured using the F. Duane's cardiac atlas. Dose distribution to cardiac chambers, left main (LM), left anterior descending (LAD), left circumflex (LCx) and right coronary artery (RCA)) was assessed. Dosimetric associations were analysed. The mean MHD was 3.08Gy (EQD2=3.67Gy). The mean Dmean/Dmax LAD was 11.45Gy (EQD2=13.64Gy)/29.5Gy (EQD2=35.15Gy). Low doses were delivered to LM, LCx, and RCA (Dmean≤1.3Gy). The left ventricle (LV) was the most exposed cardiac chamber with Dmean/Dmax of 4.78Gy/37Gy. The strongest correlation with MHD was found for Dmean LAD (r=0.81). For every 1Gy increase in MHD, Dmean LAD rose by 3.4Gy. However, the proportion of variance in Dmean LAD predictable from MHD was moderate (R Our study showed high exposure of LAD and LV in LBCRT. With poor predictive value, MHD may underestimate doses to cardiac substructures. For optimal heart sparing radiotherapy, we recommend to consider LV and LAD as separate organ at risk.

Identifiants

pubmed: 33423965
pii: S1278-3218(20)30353-X
doi: 10.1016/j.canrad.2020.09.003
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

229-236

Informations de copyright

Copyright © 2020 Société française de radiothérapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.

Auteurs

Z Naimi (Z)

University of Tunis El Manar, Faculty of Medicine of Tunis, 1007 Tunis, Tunisia; Department of Radiation Oncology, Abderrahmen Mami Hospital, 2080 Ariana, Tunisia. Electronic address: zeinebnaimi89@gmail.com.

R Moujahed (R)

University of Tunis El Manar, Faculty of Medicine of Tunis, 1007 Tunis, Tunisia; Department of Radiation Oncology, Abderrahmen Mami Hospital, 2080 Ariana, Tunisia.

H Neji (H)

University of Tunis El Manar, Faculty of Medicine of Tunis, 1007 Tunis, Tunisia; Department of Radiology, Abderrahmen Mami Hospital, 2080 Ariana, Tunisia.

J Yahyaoui (J)

Department of Radiation Oncology, Abderrahmen Mami Hospital, 2080 Ariana, Tunisia.

A Hamdoun (A)

Department of Radiation Oncology, Abderrahmen Mami Hospital, 2080 Ariana, Tunisia.

M Bohli (M)

University of Tunis El Manar, Faculty of Medicine of Tunis, 1007 Tunis, Tunisia; Department of Radiation Oncology, Abderrahmen Mami Hospital, 2080 Ariana, Tunisia.

L Kochbati (L)

University of Tunis El Manar, Faculty of Medicine of Tunis, 1007 Tunis, Tunisia; Department of Radiation Oncology, Abderrahmen Mami Hospital, 2080 Ariana, Tunisia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH